Status:
COMPLETED
Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborating Sponsors:
Otsuka America Pharmaceutical
Conditions:
Schizophrenia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Men and women, ages 18 and older, with a worsening of schizophrenia symptoms over the past three months
Exclusion
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
End Date :
September 1 2004
Estimated Enrollment :
370 Patients enrolled
Trial Details
Trial ID
NCT00080327
Start Date
November 1 2003
End Date
September 1 2004
Last Update
November 11 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bristol-Meyers Squibb Call Center
Wallingford, Connecticut, United States